Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Vaxil Bio Ltd.
  6. News
  7. Summary
    VXL   CA92243L1076

VAXIL BIO LTD.

(VXL)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vaxil Bio Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021

08/30/2021 | 05:20pm EDT

Vaxil Bio Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was CAD 209,000 compared to CAD 291,000 a year ago. Net loss was CAD 209,000 compared to CAD 297,000 a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago. For the half year, operating loss was CAD 467,000 compared to CAD 462,000 a year ago. Net loss was CAD 467,000 compared to CAD 470,000 a year ago. Basic eps - continuing operations was CAD 0 compared to basic loss per share from continuing operations of CAD 0.01 a year ago.


ę S&P Capital IQ 2021
All news about VAXIL BIO LTD.
03:22aVAXIL BIO : Signs letter of intent to acquire a 100% interest in short wave pharma inc.
PU
10/15VAXIL BIO : Announces progress on research and development activities
PU
10/14VAXIL BIO : Reports Letter of Intent to Buy 100% Interest in Short Wave Pharma; Up 10%
MT
10/14VAXIL BIO : IIROC Trading Resumption - VXL
AQ
10/14VAXIL BIO : Reports Letter of Intent to Buy 100% Interest in Short Wave Pharma
MT
10/14VAXIL BIO : Signs Letter of Intent to Acquire a 100% Interest in Short Wave Pharma Inc.
AQ
10/14VAXIL BIO : IIROC Trading Halt - VXL
AQ
10/12VAXIL BIO : up 21% as Provides Update on Research and Development Activities
MT
10/12VAXIL BIO : Provides Update on Research and Development Activities
MT
10/12VAXIL BIO : IIROC Trading Resumption - VXL
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -1,36 M -1,10 M -1,10 M
Net cash 2020 1,50 M 1,21 M 1,21 M
P/E ratio 2020 -22,5x
Yield 2020 -
Capitalization 13,7 M 11,0 M 11,0 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 91,5%
Chart VAXIL BIO LTD.
Duration : Period :
Vaxil Bio Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXIL BIO LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Managers and Directors
Yuval Avnir Chief Executive Officer
Gadi Levin Chairman & Chief Financial Officer
Terry F. Plasse Chief Medical Officer
Ari S. Kellen Independent Director
Shawn Langer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VAXIL BIO LTD.-66.67%11
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414